Stay up-to-date on new clinical findings in Oncoderm.
Oncoderm Articles
NECOM 3: A Practical Algorithm for the Management of Radiation Therapy-Related Acute Radiation Dermatitis
Background: In the Nordic European countries in 2020, cancer diagnoses accounted for 175,925 patients. About 50% of cancer patients receive radiation therapy (RT), which may lead to radiation dermatitis (RD).
USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events
Background: In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibitor (ICI).
The Interventions to Minimize Pain During Photodynamic Therapy With 5-Aminolevulinic Acid for the Treatment of Cutaneous Diseases
Background: To investigate the effectiveness, safety, patient satisfaction, and cosmetic outcome of Methyl Aminolevulinate-Photodynamic Therapy (MAL-PDT) following curettage in order to make recommendations for its use in dermatology practices.
Non-Invasive Treatment of Basal Cell Carcinoma: Photodynamic Therapy Following Curettage
Photosensitization with 5-aminolevulinic acid (ALA) combined with photodynamic therapy (PDT) is approved in the United States for the treatment of actinic keratosis (AK) and is used off-label for other indications including acne treatment and photo rejuvenation.
Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review
Background: Monoclonal antibodies encompass an increasingly important treatment for a variety of dermatologic conditions including hidradenitis suppurativa (HS). The high failure rate and cost of anti-tumor necrosis alpha (TNF-α) agents and emergence of biologic treatments critically warrant treatment strategies that identify treatment failures early and optimize therapy. This review’s primary objective is to understand the current literature on biologic therapeutic drug monitoring (TDM) used in chronic inflammatory diseases and apply this knowledge to future dermatologic studies and treatment.
Utility of Gene Expression Profiling in Skin Cancer: A Comprehensive Review
Understanding the metastatic potential of a skin cancer is essential to effective management. Gene expression profiling (GEP) is an innovative technology that has allowed for a better understanding of tumor biology in various skin cancers. Current methods focus on identifying and quantifying ribonucleic acid (RNA) transcripts in tissue samples. Using reverse transcriptase-polymerase chain reaction, specific RNA transcripts are reverted into deoxyribonucleic acid (DNA) for quantification…
Assessing the Efficacy of Imiquimod Use in Patients With Persistent Locally Advanced Melanoma In Situ
Background: The standard of care when treating melanoma in situ (MMIS) is an excision with at least 5 mm surgical margins.1 Some studies have suggested up to 9 mm margins to maximize local recurrence-free survival.2 This retrospective review aims to assess the efficacy of imiquimod as a topical treatment for persistently positive MMIS at the margins of prior excisions or where surgery is not an option.
Diversifying the Mohs Workforce: Understanding Barriers of Applicants to Mohs Micrographic Surgery Fellowship
Background: The population of the United States is becoming increasingly diverse, yet dermatology, especially Mohs micrographic surgery (MMS), lags behind.
Oncoderm Editorials
Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine and Discussion of Treatment
Shah M, Wald J, Hanke CW. Eruptive Squamous cell carcinomas following treatment with fludarabine and discussion of treatment. J Drugs Dermatol. 2023;22(5):509-510.
Dilute Intralesional 5-Fluorouracil for the Treatment of Squamous Cell Carcinomas and Keratoacanthomas: A Case Series
Background: Intralesional 5-fluorouracil (5-FU) is a promising, yet sparsely studied alternative to surgical treatment for nonmelanoma skin cancer (NMSC).1 Previous studies of intralesional 5-FU have reported concentrations ranging from 30 to 50 mg/mL. To the best of our knowledge, this case series represents the first reported use of intralesional 5-FU 10.0 mg/mL and 16.7 mg/mL for NMSC.
Advertisement
Podcasts
It Take A Village: Supportive Oncodermatology Perspectives from Oncology Nurse Leaders
The management of any cancer can require a multidisciplinary approach. One of which, until recently, often left the skin side effects on the side walk. Supportive Oncodermatology is positioned to change all that, but to do so requires a team based approach for success. In Part 3 of this supportive oncodermatology mini-series supported by La Roche-Posay, podcast host Dr. Adam Friedman is joined by Dr. Margaret Barton-Burke, PhD, RN, FAAN, Director of Nursing Research at Memorial Sloan Kettering Cancer Center in New York City, and Angela Adames, BSN, RN, OCN, a clinical nurse IV and office practice nurse in the department of radiation oncology at MSKCC, to see this specialty through a different lens. Collaboration is the name of the game and there is plenty of opportunity to do so – tune in to hear how and join the fight against oncologic therapy side effects.
Saving Skin, Hair & Nails with Supportive Oncodermatology: A Call to Action for All Those Involved
Heal the Burn: Radical Updates for the Management of Radiation Dermatitis
Supplements
United States Cutaneous Oncodermatology Management (USCOM) III: A Multidisciplinary-Guided Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events in Cancer Patients
In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibitor (ICI). Cutaneous immune-related adverse events (cirAEs) from ICIs are common and include pruritus as well as maculopapular, eczematous, bullous, lichenoid, and psoriasiform reactions. All clinicians interfacing with cancer patients must expedite proper evaluation and diagnosis, treatment, and/or consultation that supports the need for evidence-directed guidelines.
Nordic European Cutaneous Oncodermatology Management (NECOM) 3: A Practical Algorithm for Acute Radiation Dermatitis Management for Cancer Patients Receiving Radiation Therapy
In the Nordic European countries in 2020, cancer diagnoses accounted for 175,925 patients. About 50% of cancer patients receive radiation therapy (RT), which may lead to radiation dermatitis (RD). Notably, patients with breast, head, neck, and anal cancers may be prone to developing RD. However, few algorithms exist for the prevention and treatment of RD.
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm
An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients’ quality of life and interrupt anticancer treatment. The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients’ and survivors’ quality of life by offering tools for preventing and managing cAEs.